| Literature DB >> 36227397 |
Clara Berdasco1,2, Alipio Pinto1,2, Mariano G Blake1,3, Fernando Correa4, Nadia A Longo Carbajosa5,6, Ana B Celi1,2, Patricia A Geoghegan7, Adriana Cangelosi7, Myriam Nuñez8, Mariela M Gironacci5,6, Jorge Goldstein9,10.
Abstract
Shiga toxin 2 (Stx2) from enterohemorrhagic Escherichia coli (EHEC) produces hemorrhagic colitis, hemolytic uremic syndrome (HUS), and acute encephalopathy. The mortality rate in HUS increases significantly when the central nervous system (CNS) is involved. Besides, EHEC also releases lipopolysaccharide (LPS). Many reports have described cognitive dysfunctions in HUS patients, the hippocampus being one of the brain areas targeted by EHEC infection. In this context, a translational murine model of encephalopathy was employed to establish the deleterious effects of Stx2 and the contribution of LPS in the hippocampus. The purpose of this work is to elucidate the signaling pathways that may activate the inflammatory processes triggered by Stx2, which produces cognitive alterations at the level of the hippocampus. Results demonstrate that Stx2 produced depression-like behavior, pro-inflammatory cytokine release, and NF-kB activation independent of the ERK1/2 signaling pathway, while co-administration of Stx2 and LPS reduced memory index. On the other hand, LPS activated NF-kB dependent on ERK1/2 signaling pathway. Cotreatment of Stx2 with LPS aggravated the pathologic state, while dexamethasone treatment succeeded in preventing behavioral alterations. Our present work suggests that the use of drugs such as corticosteroids or NF-kB signaling inhibitors may serve as neuroprotectors from EHEC infection.Entities:
Keywords: Cell signaling; Cognitive deficits; Dexamethasone; Hippocampus; Lipopolysaccharides; Microglia; Shiga toxin
Year: 2022 PMID: 36227397 DOI: 10.1007/s10571-022-01298-1
Source DB: PubMed Journal: Cell Mol Neurobiol ISSN: 0272-4340 Impact factor: 4.231